Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Journal of Nuclear Medicine

Andreas Bockisch¹  Christian Buchbender¹  Thomas C. Lauenstein¹  Till A. Heusner¹  Gerald Antoch¹ 

关键词: MRI;    PET;    PET/MRI;    oncology;   

DOI  :  10.2967/jnumed.112.109306

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

With integrated whole-body PET/MRI, a novel metabolic–anatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone.

【 授权许可】

Unknown